血脂康胶囊治疗合并高脂血症的非酒精性脂肪性肝病

目的:初步观察血脂康对合并高脂血症的非酒精性脂肪性肝病患者的疗效。方法:48例非酒精性脂肪性肝病合并高脂血症的患者予小剂量血脂康治疗6月,并以同期正常人32例为对照,检测治疗前后体重指数、B超、肝功、血脂、及空腹血糖、空腹胰岛素等指标,采用McAuley指数及稳态模式评估法中胰岛素抵抗指数评价胰岛素抵抗,部分患者行肝组织活检对照治疗前后组织学改变。结果:胰岛素抵抗指标在非酒精性脂肪性肝病患者中明显升高,经治疗后,胰岛素抵抗指标及血脂、转氨酶水平下降,部分患者的肝组织学指标改善、未发现肝毒性。结论:小剂量血脂康用于治疗非酒精性脂肪性肝病合并高脂血症是安全有效的。

Treating non-alcoholic fatty liver disease accompanied by hyperlipidemia with Xuezhikang Capsule

AIM: To study the curative effect of Xuezhikang Capsule on non-alcoholic fatty liver disease accompanied by hyperlipidemia. METHODS: Small dosage of Xuezhikang Capsules had been administrated to the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia for 6 months. 32 healthy people had been chosen as control group at the same time. At the time points of before and after curing, body weight index. Type B ultrasonic, liver function, serum lipids, serum glucose and insulin levels had been tested. The McAuley index and the insulin resistance index of the homeostasis model assessment had been taken to evaluate insulin resistance. Liver biopsy had been conducted in some of the patients to compare the tissue changes before and after curing. RESULTS: After being treated with Xuezhikang Capsule, levels of insulin resistance serum lipids and ALT/AST in the patients with non-alcoliolic fatty liver disease had gone downward markedly. The histological observation in some of the patients had improved. No toxicity had been found. CONCLUSION: It is safe and potent to take the small dosage of Xuezhikang Capsule to cure the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia.